Navigation Links
Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
Date:10/29/2010

ivery of these outstanding quarterly results, we're building our business for the future. We're investing to enhance the value of our product pipeline, building our international structure to maximise the global reach of our products and using our strong cash generation to complete value enhancing acquisitions and in-licenses.

We now expect to see Non GAAP earnings of up to $4.20 per ADS for the full year. This includes the financial effect of the Movetis acquisition and the DAYTRANA disposal. Looking ahead, we re-iterate our aspirational target of mid-teens sales growth on average between 2009 and 2015."

FINANCIAL SUMMARY Third Quarter 2010 Unaudited Results Q3 2010 Q3 2009 Non Non US GAAP Adjustments GAAP US GAAP Adjustments GAAP $M $M $M $M $M $M Revenues 874 - 874 667 - 667 Operating income 156 142 298 92 42 134 Diluted earnings per ADS $0.52 $0.64 $1.16 $0.33 $0.16 $0.49

The Non GAAP financial measures included within this release are explained on page 26, and are reconciled to the most directly comparable financial measures prepared in accordance with US GAAP on pages 21 - 24.

- Product sales were up 32% to $794 million (2009: $603 million) due to growth from both Core Products Sales (up 31% to $694 million) and ADDERALL XR(R), (up 41% to $100 million). On a CER basis, which is a Non GAAP measure, Core Product Sales were up 34%. - Core Products Sales growth was driven by both existing and new products, particularly REPLAGAL(R) (up 91% to $92 million; CER: up 103%), VYVANSE(R) (up 17% to $151 million) and recently launched VPRIV(R) ($50 million) and INTUNIV(R) ($37 million). - Total revenues were up 31% (CER: up 34%) to $874 million (2009: $667 million), as a result of higher product sales and higher royalty income on authorized generic sales of ADDERALL XR compared to Q3 2009. - Non GAAP operating income increased by $164 million, or 123%, to $298 million (2009: $134 million) as the increased investments we are making in our
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
2. Reportlinker Adds Shire plc: PharmaVitae Profile
3. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
4. Shire plc - Statement re ProAmatine
5. Shire Proposes to Expand Specialist Gastrointestinal Portfolio
6. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
7. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
8. Shire plc Appoints Two New Board Directors
9. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
10. Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
11. INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... -- Bionomics Limited (ASX:BNO, ADR:BMICY) is to present important ... patients with metastatic renal cancer at the ASCO Genitourinary ... The data will be presented by Dr. Sumanta ... Center in California in his ... Ferritin and IL-8 as two baseline biomarkers that correlate ...
(Date:2/27/2015)... BOSTON , Feb. 27, 2015   PureTech ... identifying, inventing and commercializing disruptive products and technologies in ... Christopher Viehbacher , former CEO and Member of the ... Directors.  "It,s has been a pleasure ... very excited that we will be working together more ...
(Date:2/26/2015)... 2015   Synageva BioPharma Corp. (NASDAQ: ... therapeutic products for rare disorders, today reported 2014 ... other key objectives, and financial guidance.  Synageva,s management ... 4:30 p.m. EST to review the financial results ... in today,s call by telephone, please dial (877) ...
(Date:2/26/2015)... On behalf of biotech client GenScript ... Goldman & Spitzer, P.A. (Wilentz) secured a significant ... Inc. in excess of $10 million. The jury determined ... and that it improperly hired one or more of ... motions for judgment notwithstanding the verdict, a new trial, ...
Breaking Biology Technology:New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
... hemostatic powder is available in ready-to-use applicator, ATLANTA, ... biomaterials, medical device and tissue processing company, announced,today that ... Hemostase MPH for use in general, cardiac and vascular ... U.S., the United,Kingdom and Germany in the second quarter ...
... References to the Brazilian,ethanol industry in the ... the Amsterdam-based non-government organization Friends of,the Earth, ... outdated,information that in no way reflects current ... comes from Marcos Sawaya Jank, president of ...
... and Products Offset Patent Expirations, SAN FRANCISCO, ... of major neuropathic pain (NP) conditions is currently ... a report released today by,WWMR, Inc. Growth over ... by the,successful launch of Lyrica (pregabalin) for diabetic ...
Cached Biology Technology:CryoLife Expands Distribution of Hemostase MPH(R) to France through Laboratoire Gamida 2CryoLife Expands Distribution of Hemostase MPH(R) to France through Laboratoire Gamida 3Friends of the Earth Report on Biofuel Production Offers Incomplete, Outdated and Inaccurate Picture, According to Brazilian Sugarcane Industry Association 2Friends of the Earth Report on Biofuel Production Offers Incomplete, Outdated and Inaccurate Picture, According to Brazilian Sugarcane Industry Association 3US Neuropathic Pain Market Value Doubles to $5 Billion by 2018 2US Neuropathic Pain Market Value Doubles to $5 Billion by 2018 3
(Date:2/5/2015)... , Jan. 28, 2015 Research and ... the addition of the "Global Biometrics Market ... Regions and Countries " report to their offering. ... Asia-Pacific is anticipated to ... 2015, owing to increasing government spending towards IT ...
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading ... the launch of its new website design. "When ... its infancy", says Peter O,Neill , founder and CEO ... the industry needs involvement from the key players on a ...
(Date:1/22/2015)... NXTD and NXTDW) a biometric authentication company focused on ... Wocket™ smart wallet at CES 2015 in Las Vegas ... the "11 Hot Products at CES" in a review published in Wired.com, ... Newseveryday.com and "The top 10 gadgets from CES 2015" by Danny ...
Breaking Biology News(10 mins):Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
... Dr. William Phillips, an Office of Naval Research ... lecture at ONR,s spring distinguished lecture series May ... the Coolest Stuff," highlighted the importance of basic ... scientists. Among the attendees at Phillips, lecture ...
... . , It is the concentration of a few ... the early development of organisms. In the renowned journal ... Pia Aanstad of the University of Innsbruck reports that a ... concentration of the signaling molecule Hedgehog. The development ...
... Stockholm, Sweden and Addis Ababa, Ethiopia Current research ... The related report by Rahman et al, "Compartmentalization of ... cells but elevated levels of FoxP3+ regulatory T cells ... issue of The American Journal of Pathology . ...
Cached Biology News:Nobel Laureate underscores importance of investment in basic research 2Why the thumb of the right hand is on the left hand side 2TB -- hiding in plain sight 2
... Ligands\n\nReceptor-related research has long been enabled by ... selected to keep pace with new discoveries. ... and services for receptor research and drug ... you do not find exactly what you ...
... UltraPure Agarose and SYBR Safe DNA Gel Stain ... Saves money versus buying these same products separately ... alternative to ethidium bromide ... Agarose resolves DNA and RNA fragments from 100 bp ...
... Odyssey images are easily imported for data analysis , ... ... , Extensive background and signal options to optimize, ... results , ...
... optimized for siRNA applications, contains magnetic nanoparticles ... nucleic acid of interest. Exploiting magnetic force ... rapidly drawn towards and delivered into the ... Reagent can be used for adherent cells; ...
Biology Products: